Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Germline analysis of thymidine/guanidine polymorphism at position 309 of the Mdm2 promoter in malignant melanoma patients.

Melanoma research - 1 Aug 2009

Gluck Iris, Simon Amos J, Catane Raphael, Pfeffer Raphael, Schachter Jacob, Rechavi Gideon, Bar Jair

Abstract excerpt

p53 is a major tumor suppressor gene, frequently mutated in human cancer, but rarely mutated in malignant melanoma (MM). Mdm2, the major negative regulator of p53, is overexpressed in 50-60% of MM patients, by an unknown mechanism. Single nucleotide polymorphism at position 309 of the Mdm2 promoter correlates with increased Mdm2 levels and reduced p53 activation. We speculated that guanine at position 309 (G309)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aging
Share to Germ Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Proto-Oncogene Proteins c-mdm2

Share to Sex Characteristics

Share to Skin Neoplasms

Share to Thymidine

Source

Identifiers

PMID: 19455066
DOI: 10.1097/CMR.0b013e32832ccd27

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Germline analysis of thymidine/guanidine polymorphism at position 309 of the Mdm2 promoter in malignant melanoma patients.PMID 19455066Read ↗

MDM2 T309G polymorphism is associated with bladder cancer.Semantic proximity Read ↗

Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma.Semantic proximity Read ↗

Significance of MDM2-309 polymorphisms and induced corresponding plasma MDM2 levels in susceptibility to laryngeal squamous cell carcinoma.Semantic proximity Read ↗

MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies.Semantic proximity Read ↗

Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer.Semantic proximity Read ↗

MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis.Semantic proximity Read ↗

Impact of MDM2 polymorphism: increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population.Semantic proximity Read ↗

Single nucleotide polymorphism 309 affects murin-double-minute 2 protein expression but not glioma tumorigenesis.Semantic proximity Read ↗

MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis.Semantic proximity Read ↗

Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development.Semantic proximity Read ↗

MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness.Semantic proximity Read ↗

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.